Pravastatin Ratiopharm 20 mg tabletti Phần Lan - Tiếng Phần Lan - Fimea (Suomen lääkevirasto)

pravastatin ratiopharm 20 mg tabletti

sandoz a/s - pravastatin sodium - tabletti - 20 mg - pravastatiini

Pravastatin Ratiopharm 40 mg tabletti Phần Lan - Tiếng Phần Lan - Fimea (Suomen lääkevirasto)

pravastatin ratiopharm 40 mg tabletti

sandoz a/s - pravastatin sodium - tabletti - 40 mg - pravastatiini

Pravastatin Orion 20 mg tabletti Phần Lan - Tiếng Phần Lan - Fimea (Suomen lääkevirasto)

pravastatin orion 20 mg tabletti

orion corporation - pravastatin sodium - tabletti - 20 mg - pravastatiini

Pravastatin Orion 40 mg tabletti Phần Lan - Tiếng Phần Lan - Fimea (Suomen lääkevirasto)

pravastatin orion 40 mg tabletti

orion corporation - pravastatin sodium - tabletti - 40 mg - pravastatiini

Thalidomide Lipomed Liên Minh Châu Âu - Tiếng Phần Lan - EMA (European Medicines Agency)

thalidomide lipomed

lipomed gmbh - talidomidin - multiple myeloma - immunosuppressantit - thalidomide lipomed in combination with melphalan and prednisone is indicated as first line treatment of patients with untreated multiple myeloma, aged ≥ 65 years or ineligible for high dose chemotherapy. thalidomide lipomed is prescribed and dispensed in accordance with the thalidomide lipomed pregnancy prevention programme (see section 4.

Melphalan Macure 50 mg injektio/infuusiokuiva-aine ja liuotin, liuosta varten Phần Lan - Tiếng Phần Lan - Fimea (Suomen lääkevirasto)

melphalan macure 50 mg injektio/infuusiokuiva-aine ja liuotin, liuosta varten

macure pharma aps - melphalan hydrochloride - injektio/infuusiokuiva-aine ja liuotin, liuosta varten - 50 mg - melfalaani

Dexliq 4 mg/ml oraaliliuos Phần Lan - Tiếng Phần Lan - Fimea (Suomen lääkevirasto)

dexliq 4 mg/ml oraaliliuos

laboratoires ctrs - dexamethasone sodium phosphate - oraaliliuos - 4 mg/ml - deksametasoni

Brukinsa Liên Minh Châu Âu - Tiếng Phần Lan - EMA (European Medicines Agency)

brukinsa

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastiset aineet - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).

Farydak Liên Minh Châu Âu - Tiếng Phần Lan - EMA (European Medicines Agency)

farydak

pharmaand gmbh - panobinostaatti-laktaatti vedettömänä - multiple myeloma - antineoplastiset aineet - farydak, yhdessä bortetsomibin ja deksametasonia, on tarkoitettu kohtelu aikuispotilailla, joilla on uusiutunut ja/tai tulenkestävät multippeli myelooma jotka ovat saaneet vähintään kaksi ennen hoito kuten bortetsomibin ja immunomodulatorisia agentti. farydak, yhdessä bortetsomibin ja deksametasonia, on tarkoitettu kohtelu aikuispotilailla, joilla on uusiutunut ja/tai tulenkestävät multippeli myelooma jotka ovat saaneet vähintään kaksi ennen hoito kuten bortetsomibin ja immunomodulatorisia agentti.

Thalidomide BMS (previously Thalidomide Celgene) Liên Minh Châu Âu - Tiếng Phần Lan - EMA (European Medicines Agency)

thalidomide bms (previously thalidomide celgene)

bristol-myers squibb pharma eeig - talidomidin - multiple myeloma - immunosuppressantit - thalidomide bms in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged >/= 65 years or ineligible for high dose chemotherapy. thalidomide bms is prescribed and dispensed according to the thalidomide celgene pregnancy prevention programme (see section 4.